

# Detection of Vancomycin Resistance among *Enterococcus faecalis* and *Staphylococcus aureus*

RAMYA RENGARAJ<sup>1</sup>, SHANTHI MARIAPPAN<sup>2</sup>, UMA SEKAR<sup>3</sup>, ARUNAGIRI KAMALANADHAN<sup>4</sup>

## ABSTRACT

**Introduction:** Vancomycin remains the drug of choice for resistant gram positive infections caused by *Enterococcus* spp and Methicillin resistant *Staphylococcus aureus* (MRSA). Increased use of vancomycin has led to frank resistance and increase in MIC (MIC creep). Vancomycin intermediate *Staphylococcus aureus* (VISA), Vancomycin resistant *Staphylococcus aureus* (VRSA) & Vancomycin resistant *Enterococci* (VRE) are important emerging nosocomial pathogens resulting in treatment failures.

**Aim:** This study was undertaken to detect vancomycin resistance among clinical isolates of *Staphylococcus aureus* and *Enterococcus faecalis* by phenotypic and genotypic methods.

**Materials and Methods:** The study was conducted in a 1850 bedded university teaching hospital from November 2013 to April 2014. Non-repetitive, consecutive clinically significant *Staphylococcus aureus* (109) and *Enterococcus faecalis* (124) were included in this study. They were identified up to species level by conventional and automated methods. Susceptibility to various antibiotics was tested by disc diffusion method. MIC of

vancomycin was determined by agar dilution method. Inducible resistance to clindamycin was detected by the D test. Methicillin resistance in *Staphylococcus aureus* (MRSA) was screened using cefoxitin disc. All isolates were subjected to polymerase chain reaction (PCR) to detect van A and van B genes.

**Results:** Out of 109 *Staphylococcus aureus* isolates, 54 were MRSA. By MIC there was no resistance observed to vancomycin. MIC<sub>50</sub> was 1µg/ml. None of the isolates harboured van A and van B. Among *Enterococcus faecalis*, sixteen isolates (12.9%) and four isolates (3.2%) exhibited resistance to vancomycin and teicoplanin by disc diffusion respectively. All isolates were susceptible to linezolid. Van A was detected in 2, van B in 7 and one had both van A and van B.

**Conclusion:** PCR remains the gold standard for diagnosis of vancomycin resistance. There was no resistance observed to vancomycin among *Staphylococci* though the MIC creep detected is a cause for concern. Eight percent of *Enterococci* were vancomycin resistant.

**Keywords:** Mec C, MRSA, van A genotype-van B phenotype incongruency, VRE, VRSA

## INTRODUCTION

Glycopeptide antibiotics remain the drug of choice for infections caused by resistant *Enterococcus* species and Methicillin Resistant *Staphylococcus aureus* (MRSA). Enterococci with a MIC of  $\geq 32\mu\text{g/ml}$  are classified as vancomycin resistant *Enterococci* (VRE). *Staphylococcus aureus* isolates with a MIC of 4-8µg/ml are termed as Vancomycin Intermediate *Staphylococcus aureus* (VISA) and those with a MIC of  $\geq 16\mu\text{g/ml}$  are termed as Vancomycin Resistant *Staphylococcus aureus* (VRSA). Vancomycin resistant *Enterococci* have emerged as important nosocomial pathogens in the last two decades throughout the world [1]. VRE are associated with many infections ranging from mild to life threatening. Extensive use of vancomycin to treat infections with MRSA has led to decreased susceptibility to vancomycin among *Staphylococcus aureus*. As of today very limited options are available for treating serious infections caused by VRE and VRSA [1].

VISA, VRSA and VRE are important nosocomial emerging pathogens resulting in treatment failures. This study was undertaken to detect vancomycin resistance among *Staphylococcus aureus* and *Enterococcus faecalis* isolates by both phenotypic and genotypic methods.

## MATERIALS AND METHODS

### Study Isolates

The study was conducted in a 1850 bedded university teaching hospital from November 2013 to April 2014. Institutional ethics committee approval was obtained. Bacterial isolates consisting of

non-repetitive, consecutive clinically significant *Staphylococcus aureus* (109) and *Enterococcus faecalis* (124) were included in this study. *Staphylococcus aureus* isolates were collected from blood (8), respiratory (2) and exudative (99) samples. The *Enterococcus faecalis* were collected from urine (57) and exudative (67) samples.

The exclusive criteria included the isolates from non admitted patients and the isolates which were not clinically significant. The isolates were speciated by using routine biochemicals and automations. (Microscan Walk Away 96).

### Antibiotic Susceptibility

#### Disc Diffusion

Antibiotic susceptibility was tested with gentamycin (10µg), ciprofloxacin (5µg), erythromycin (10µg), clindamycin (2µg), teicoplanin (30µg) and linezolid (30µg) for *Staphylococcus aureus* by disc diffusion method according to Clinical Laboratory Standards Institute (CLSI) guidelines [2]. For *Enterococcus faecalis*, antibiotic susceptibility was tested with high level gentamycin (120µg), ciprofloxacin (5µg), vancomycin (30µg), teicoplanin (30µg) and linezolid discs (30µg) for all isolates, erythromycin (10µg) for exudative isolates, nitrofurantoin (300µg) for urinary isolates by disc diffusion method [2]. All the discs were procured from Hi-media laboratories, Mumbai, Maharashtra, India.

### Minimum inhibitory concentration

MIC of vancomycin for all the test isolates was determined by agar dilution method; the range tested being 0.008µg/ml to 256µg/ml in accordance to CLSI guidelines [2].

## Phenotypic Tests

Induced resistance for clindamycin was detected by D test. Methicillin resistant *Staphylococcus aureus* (MRSA) was screened using cefoxitin disc (30 µg).

## Molecular Detection of Genes

All the isolates were subjected to PCR targeting van A and van B. *Staphylococci* isolates were tested for mec A also. A single colony was inoculated in Luria-Bertini broth and incubated for 20 hours with shaking in between and 1.5 ml of this was centrifuged for 5 minutes. The pellets were suspended in 500 µl of distilled water and lysed by heating at 95°C for 5 minutes and centrifuged for 1 minute. Fiveµl of this extract was used as a template for amplification. The following is the list of primers used [Table/Fig-1].

PCR Conditions: Initial denaturation - 95°C - 3 min

Denaturation - 94°C - 1 min

Annealing - 56°C - 1 min (van A & van B)

Extension - 72°C - 1 min

Final Extension - 72°C - 5 min

PCR Product: PCR Product of 782 bp (van A) & 297 bp (van B) were visualised by Agarose gel electrophoresis.

Primer	Primer sequence 5'-3'	Product size	annealing temperature
van A	P1 = GCT ATTCAG CTG TAC TC P2 = CAG CGG CCA TCA TAC GG	783 bp	56°C
van B	P1 = CAT CGC CGT CCC CGA ATT TCA AA P2 = GAT GCG GAA GAT ACC GTC GCT	297 bp	56°C
Mec A	F = ATC GAT GGT AAA GGT TGG C R = AGT TCT GCA GTA CCG GAT TTG C	530 bp	58°C

[Table/Fig-1]: Primer Sequence for van A, van B and mec A [3]

## RESULTS

### Disc Diffusion (*Staphylococcus aureus*)

Fifty four isolates were resistant to cefoxitin disc (MRSA). The resistance to gentamycin, ciprofloxacin, erythromycin are 36.6%, 57.7% and 41.2% respectively. Constitutive resistance to clindamycin was 20.1%. All isolates were susceptible to teicoplanin and linezolid. By D test 10% of the isolates exhibited inducible resistance to clindamycin.

### Disc Diffusion (*Enterococcus faecalis*)

The resistance to high level gentamycin, ciprofloxacin, erythromycin and nitrofurantoin were 45.6%, 79.03%, 76.19% and 38.18% respectively. Vancomycin and teicoplanin resistance was exhibited in 12.9%(16) and 3.2%(4) isolates respectively. All isolates were susceptible to linezolid.

### Minimal Inhibitory Concentration

#### *Staphylococcus aureus*

MIC of vancomycin ranged from 0.125µg/ml to 2µg/ml. MIC<sub>50</sub> was 1µg/ml. There was no resistance observed to vancomycin.


#### *Enterococcus Faecalis*

MIC ranged between 0.25-256 µg/ml. MIC<sub>50</sub> was 1 µg/ml. 4 isolates were resistant to vancomycin. Two of them had MIC of >256µg/ml, one with a MIC of 256µg/ml and one with a MIC of 128µg/ml. Two were in the intermediate range with a MIC of 8 µg/ml and 16µg/ml.

### Polymerase Chain Reaction

#### *Staphylococcus aureus*

Mec A gene was detected in 15 isolates. None of the isolates were positive for van A and van B.



### *Enterococcus faecalis*

Two isolates harboured van A and seven isolates harboured van B. In one isolate both van A and van B genes were detected [Table/Fig-2].

### Comparative Results of MIC and PCR

Out of 4 isolates which were resistant by MIC, one isolate (MIC>256µg/ml) was positive for van A. Other three were neither van A nor van B positive. Out of 2 isolates with van A, one had MIC in resistant range (256µg/ml), other with MIC in intermediate range (16µg/ml). All seven isolates with van B had MIC in a susceptible range (1µg/ml). The isolate with both van A and van B had a MIC in intermediate range (8 µg/ml).

## DISCUSSION

Vancomycin is a glycopeptide discovered as early as 1950. It acts by preventing synthesis of peptidoglycan precursors of cell wall by blocking transglycosylation and transpeptidation steps essential for cross linking. Site of action is on D-ala D-ala residue of the polypeptide [1]. Vancomycin has been used as the drug of choice in serious infections caused by MRSA and resistant *Enterococci*. Resistance of these organisms to vancomycin is being reported since last two decades. Vancomycin intermediate *Staphylococcus aureus* was first reported by Hirmatsu et al., from Japan in a four month old infant with pulmonary atresia in 1997 [4]. Tiwari and Sen were the first to report VISA strains from Indian subcontinent [5]. However, a fully resistant strain of *Staphylococcus aureus* to vancomycin was reported only in 2002 from Michigan, US [6].

This study included a total of 109 *Staphylococcus aureus* isolates from various samples. Fifty four isolates (49%) out of them were MRSA by cefoxitin disc diffusion method. Joshi et al., reported MRSA prevalence of around 40% [7]. Another study from Hyderabad reported MRSA as high as 79.6% [8]. Fifteen of the cefoxitin resistant isolates carried mecA. According to one study strains phenotypically resistant to cefoxitin but mec A negative may probably due to mec C [9]. The other 39 cefoxitin resistant isolates have to be further screened for mec C and other non mecA mediated resistance. The resistance to gentamycin, ciprofloxacin, erythromycin are 36.6%, 57.7% and 41.2% respectively.

All isolates of *Staphylococcus aureus* were susceptible to vancomycin with MIC<sub>50</sub> of 1µg/ml. None of the isolates harboured van A or van B by PCR. This was similar to another study conducted in South India which also reported no resistance to vancomycin by MIC [10]. Thati et al., reported 1.9% VRSA and 4.46% VISA isolates by MIC [8]. Their study also revealed high percentage of resistance among VRSA isolates to other antimicrobials also. A van gene negative VRSA was also reported by them. Tiwari and Sen also reported a van gene negative VRSA from northern part of India [5].

*Enterococci*, apart from being a part of normal microbiota also cause nosocomial infections. The first VRE was reported by Uttley et al., in 1977 from Great Britain [11]. In India, the first VRE was reported by Mathur et al., in 1999 [12]. Our study included 124 *Enterococcus faecalis* isolates 67 Of which were from exudates and 57 from urine. The resistance to high level gentamycin, ciprofloxacin, erythromycin and nitrofurantoin were 45.6%, 79.03%, 76.19% and 38.18% respectively. Another study reported resistance of 37%, 74.38% and 29% to high level gentamycin, ciprofloxacin and nitrofurantoin among *Enterococci* [13].

Van A and Van B are the most common genotypes among *Enterococci*. Van A is associated with high level resistance to both vancomycin (MIC $\geq$ 64 $\mu$ g/ml) and teicoplanin (MIC $\geq$ 16 $\mu$ g/ml). Van B is associated with varying levels of resistance to vancomycin alone (MIC 4 -1000  $\mu$ g/ml) with susceptibility to teicoplanin [14]. In this study, by MIC determination four isolates were vancomycin resistant and one isolate exhibited intermediate susceptibility to vancomycin. The isolate that harboured the van A gene had a MIC of 256 $\mu$ g/ml. The other three neither carried van A nor van B. They have to be screened for other van genes (van D, van E, van J, van L, van M) for further characterization [1]. By PCR two isolates were van A Positive. One had a MIC of 256 $\mu$ g/ml. Other had a MIC of 16  $\mu$ g/ml showing low level resistance to vancomycin. Such van A genotype –van B phenotype incongruency has also been reported in other studies in *Enterococcus faecalis* and *Enterococcus faecium* [13,15,16]. Park et al., suggested presence of insertion sequence IS 1216v in coding region of van S gene as a probable reason for this incongruency [16]. According to other authors this is due to mutations in van A gene cluster or in van S regulatory element [17,18].

Seven isolates were positive for van B. All of them had a susceptible MIC of 1  $\mu$ g/ml. Van B VRE with susceptible MIC were already reported in few studies in *Enterococcus faecium* [19,20]. The reason for this phenotype-genotype incongruence is not known. One isolate which carried both van A and van B had an MIC of 8 $\mu$ g/ml. By PCR, 8% of all *Enterococcus* isolates are VRE. Another study conducted in South India reported 8.7% VRE [11]. van B was the most common phenotype. This is in contradiction to many studies which report van A as the commonest phenotype [13,19].

## CONCLUSION

Resistance to vancomycin was not detected among isolates of *Staphylococcus aureus* both phenotypically and genotypically. However, MIC creep is a cause for concern. Among *Enterococcus faecalis* isolates, 8% were VRE by PCR. High resistance percentage to other antibiotics among *Enterococcus faecalis* isolates was also recorded. van A genotype –van B phenotype incongruence was observed in two of the test isolates. Another important finding is VRE isolates with susceptible MIC. van B was the commonest genotype. PCR remains the gold standard for diagnosis of vancomycin resistance. Emerging vancomycin resistance among

*Enterococcus faecalis* is a cause for concern as this leads to a great difficulty in treating the serious infections caused by them. Prudent use of antibiotics with good infection control practices will help to retain their susceptibility.

## REFERENCES

- [1] Sujatha S, Ira P. Glycopeptide resistance in gram-positive cocci: A review. *Interdiscip Perspect Infect Dis*. 2012;2012.
- [2] CLSI. Performance standards for Antimicrobial Susceptibility Testing; Twenty third Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
- [3] Li S, Zhang Z, Mi ZH. Vancomycin-resistant enterococci in a Chinese hospital. *Curr microbial*. 2007;55(2):125-27.
- [4] Hiramatsu K, Hanaki H, Iino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J Antimicrob Chemother*. 1997;40(1):135-36.
- [5] Tiwari HK, Sen MR. Emergence of vancomycin resistant *Staphylococcus aureus* (VISA) from a tertiary care hospital from northern part of India. *BMC Infect Dis*. 2006;6:156.
- [6] Zhu W, Clark NC, McDougal LK, Hageman J, McDonald LC, Patel JB. Vancomycin-resistant *Staphylococcus aureus* isolates associated with Inc18-like vanA plasmids in Michigan. *Antimicrob agents Chemother*. 2008;52(2):452-57.
- [7] Joshi S, Ray P, Manchanda V, Bajaj J, Chitnis DS, Gautam V, et al. Methicillin resistant *Staphylococcus aureus* (MRSA) in India: Prevalence & susceptibility pattern. *Indian J Med Res*. 2013;137(2):363-69.
- [8] Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant *Staphylococcus aureus* isolates from intensive care units of tertiary care hospitals in Hyderabad. *Indian J Med Res*. 2011;134(5):704-08.
- [9] Paterson GK, Harrison EM, Holmes MA. The emergence of mecC methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol*. 2014;22(1):42-7.
- [10] Ramakrishna N, Reddy BK, Murthy DS. Detection of vancomycin resistance among clinical isolates of *Staphylococcus aureus* in a tertiary hospital, tirupati. *Int J Res Health Sci*. 2014;2(4):1150-56.
- [11] Uttley AH, George RC, Naidoo J, Woodford N, Johnson AP, Collins CH, et al. High-level vancomycin-resistant enterococci causing hospital infections. *Epidemiol Infect*. 1989;103(1):173-81.
- [12] Mathur P, Chaudhary R, Dhawan B, Sharma N, Kumar L. Vancomycin resistant *Enterococcus bacteremia* in a lymphoma patient. *Indian J Med Microbiol*. 1999; 17:194-95.
- [13] Praharaj I, Sujatha S, Parija SC. Phenotypic & genotypic characterization of vancomycin resistant *Enterococcus* isolates from clinical specimens. *Indian J Med Res*. 2013;138(4):549-56.
- [14] Centinkaya Y, Falk P, Mayhall CG. Vancomycin resistant *Enterococci*. *Clin Microbiol Rev*. 2000; 13:686-707.
- [15] Al-Ahdal MN, Abozaid SM, Al-Shammary HF, Bohol MF, Al-Thawadi SI, Al-Jaberi AA, et al. Characterization of *Enterococcus faecium* isolates and first report of vanB phenotype–vanA genotype incongruence in the Middle East. *Eur J Clin Microbiol Infect Dis*. 2012;31(11):3223-29.
- [16] Park IJ, Lee WG, Shin JH, Lee KW, Woo GJ. Van B phenotype van A genotype *Enterococcus faecium* with heterogeneous expression of teicoplanin resistance. *J Clin Microbiol*. 2008 46:3091-93.
- [17] Lee WG, Huh JY, Cho SR, Lim YA. Reduction in glycopeptide resistance in vancomycin resistant enterococci as a result of vanA cluster rearrangements. *Antimicrob Agents Chemother*. 2004 48:1379-81.
- [18] Eom JS, Hwang IS, Hwang BY, Lee JG, Lee YJ, Cheong HJ, et al. Emergence of vanA genotype vancomycin resistant enterococci with low or moderate levels of teicoplanin resistance in Korea. *J Clin Microbiol*. 2004 42:1785-86.
- [19] Azza LZ, Ahmed MB, Nahed AA, Wafaa ZA, Eman EA. Molecular and phenotypic characterization of hospital-associated and community-associated isolates of *Enterococcus* spp. *Menoufia Med J*. 2013;26:108-13.
- [20] Grabsch EA, Chua K, Xie S, Byrne J, Ballard SA, Ward PB, Grayson ML. Improved detection of vanB2-containing *Enterococcus faecium* with vancomycin susceptibility by Etest using oxgall supplementation. *J Clin Microbiol*. 2008;46(6):1961-64.

### PARTICULARS OF CONTRIBUTORS:

1. Postgraduate, Department of Microbiology, SRMC, Chennai, Tamil nadu, India.
2. Associate Professor, Department of Microbiology, SRMC, Chennai, Tamil nadu, India.
3. Head of the Department, Department of Microbiology, SRMC, Chennai, Tamil nadu, India.
4. Technical Assistant, CLTRI, Chengalpet, Tamil nadu, India.

### NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Uma Sekar,  
Professor and Head, Department of Microbiology, Director, Sri Ramachandra Laboratory Services,  
Sri Ramachandra Medical College and Research Institute, Sri Ramachandra University, Porur, Chennai-600116, India.  
E-mail: umasekarsrmc@gmail.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Oct 27, 2015**  
Date of Peer Review: **Dec 15, 2015**  
Date of Acceptance: **Jan 04, 2016**  
Date of Publishing: **Feb 01, 2016**